US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.27 against a street estimate of 0.10 — a beat of 170.0%.
Analysts rate BioCryst Pharmaceuticals Inc a buy (9 buy, 2 hold, 0 sell out of 11) with an average price target of $20.55.
CONFIDENT BioCryst delivered strong Q2 with ORLADEYO growing 10% YoY, pediatric launch off to robust start (47 Rx vs. full-year expectations), and navenibart enrollment complete ahead of schedule. Cost cuts underway post-Birmingham closure. Q2 2026 Navenibart EU rights licensed to Neopharmed Gentili. Former European ORLADEYO business divested. U.S. focus for ORLADEYO growth. Analysts pressed on ORLADEYO volume breakdown (Charlie clarified 50/50 split), Netherton efficacy bar (Sandeep: first targeted KLK5 therapy; any relief major advance), and pediatric paid rates (Charlie: expect 80%+; early signs strong). Management confidence throughout; no material walk-backs. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.35% |
| RA Capital Management, LLC | 6.19% |
| State Street Corp | 5.94% |
| Deerfield Management Co | 5.91% |
| Vanguard Capital Management, LLC | 4.45% |
| Vanguard Portfolio Management, LLC | 4.36% |
| TCG Crossover Management, LLC | 4.31% |
| Perceptive Advisors LLC | 4.03% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $180,292 thousand, up from $159,395 thousand in the third quarter of 2025. • Third-quarter 2026 ne | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $180.3 million, up 13% year over year. • ORLADEYO revenue was $174.8 million, compared with $159.1 mill | 2026-11-04 |
| Quarterly report · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and equivalents: $154.972 million (June 30, 2026) vs $89.736 million ( | 2026-08-05 |
| Results announced · Q3 2026 BIOCRYST PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $218.3 million (+34% year-over-year; +45% excluding Eur | 2026-08-05 |
| Reg FD disclosure · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: June 25, 2026 (Board approval); June 29, 2026 (public announcement | 2026-06-29 |
| Board / officer change · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 • 7,000,000 additional shares approved for is | 2026-06-12 |
| Quarterly report · Q1 2026 BIOCRYST PHARMACEUTICALS, INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $171.6 million in cash and cash equivalents as of March 31, 2026 | 2026-05-06 |
| Results announced · Q2 2026 BIOCRYST PHARMACEUTICALS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 ORLADEYO net revenue: $148.3 million (+11% year-over-year; +21% exclud | 2026-05-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Increased total revenue guidance and improved non-GAAP operating expense guidance BioCryst reported a strong third quarter for its commercial drug ORLADEYO. Total revenue was $180.3 million, up 13% year over year, while ORLADEYO revenue was $174.8 million. Operating profi | 2026-11-04 |
| Maintained ORLADEYO revenue guidance, increased total revenue guidance for 2026 BioCryst Pharmaceuticals reported strong Q2 2026 results with total revenue of $218.3 million (up 34% year-over-year) and ORLADEYO net revenue of $158.2 million. The company achieved operati | 2026-08-05 |
| 2026 non-GAAP operating expense guidance improved; revenue guidance reaffirmed BioCryst Pharmaceuticals announced a strategic shift to focus on external innovation rather than internal drug discovery. The company will close its Birmingham, Alabama research facility by | 2026-06-29 |
| Licensing agreement for European navenibart rights to Neopharmed Gentili BioCryst Pharmaceuticals reported strong Q1 2026 results with ORLADEYO (its main drug for hereditary angioedema) generating $148.3 million in revenue, up 11% year-over-year. More importantly | 2026-05-06 |
| European licensing agreement for navenibart in hereditary angioedema BioCryst Pharmaceuticals signed a licensing deal with an Irish affiliate of Neopharmed Gentili to commercialize navenibart (an experimental HAE treatment) in Europe. BioCryst will receive $7 | 2026-05-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioCryst Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.